ELUT ELUT
Company Profile ↓Company Overview
ELUT (ELUT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 1.0.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $12.29M (-15.0% YoY); net profit $53.38M.
- Trailing 12 Months Year-on-year growth — revenue -15.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -18.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -18.80% |
| 1 Year: | -15.03% |
Stock Price Performance
| 1 Year: | -56.18% |
| 6 Months: | -11.02% |
| 3 Months: | -10.66% |
| 1 Month: | -9.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -18.8% CAGR over 5 years.
- Trading 63.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.14M | 9.86M | 8.58M | 11.77M | 12.88M | 12.16M | 11.48M | 11.49M | 12.64M | 5.85M | 6.39M | 6.35M | 6.13M | 6.69M | 6.29M | 3.66M | 2.95M | 6.26M | 3.32M | 3.11M |
| Gross Profit | 5.54M | 5.21M | 3.78M | 5.54M | 6.33M | 5.61M | 3.69M | 4.28M | 4.90M | 2.94M | 3.37M | 2.71M | 2.84M | 2.84M | 2.80M | 1.79M | 1.38M | 3.06M | 1.85M | 1.80M |
| Operating Income | -1.85M | -3.18M | -3.76M | -2.69M | -3.70M | -4.59M | -6.98M | -6.92M | -8.18M | -8.97M | -8.34M | -6.31M | -7.37M | -8.48M | -8.51M | -9.18M | -6.78M | -9.88M | -5.21M | -6.35M |
| Net Income | -3.10M | -4.56M | -5.18M | -6.73M | -5.07M | -2.38M | -8.32M | -8.15M | -9.40M | -9.91M | -7.97M | -10.62M | -9.75M | -17.99M | -28.18M | 1.29M | -3.93M | -9.61M | -3.87M | -7.47M |
| Diluted EPS | - | - | -7.99 | -15.79 | -0.50 | -0.23 | -0.81 | -0.60 | -0.69 | -0.73 | -0.49 | -0.65 | -0.57 | -0.75 | -1.13 | -0.33 | -0.21 | -0.26 | -0.19 | -0.17 |
| R&D Expense | 507.00K | 1.31M | 1.41M | 1.26M | 1.72M | 1.88M | 2.29M | 2.27M | 2.62M | 1.72M | 1.59M | 869.00K | 557.00K | 1.17M | 1.00M | 702.00K | 871.00K | 1.46M | 1.09M | 1.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.90M | 42.68M | 47.39M | 23.85M | 24.75M | 14.47M | 12.29M |
| Gross Profit | 19.77M | 20.56M | 19.02M | 11.64M | 11.05M | 6.71M | 6.60M |
| Operating Income | -8.41M | -13.60M | -23.03M | -35.19M | -30.53M | -30.71M | -26.91M |
| Net Income | -11.94M | -21.82M | -24.83M | -32.90M | -37.66M | -53.95M | 53.38M |
| Diluted EPS | - | -8.88 | -2.38 | -2.38 | -2.07 | -1.86 | 0.87 |
| R&D Expense | 2.40M | 5.95M | 9.27M | 7.73M | 4.40M | 3.00M | 4.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.77M | 82.81M | 67.17M | 68.84M | 43.43M | 36.13M | 62.35M |
| Total Equity | -43.41M | -55.11M | 20.83M | 13.52M | -5.03M | -38.60M | -46.26M | 27.67M |
| Cash & Equivalents | - | 2.48M | 39.15M | 30.39M | 16.99M | 19.28M | 13.24M | 36.35M |
| Long Term Debt | - | 19.61M | 17.81M | 10.41M | 24.26M | 20.36M | 22.60M | - |
| Total Liabilities | - | 55.43M | 61.98M | 53.65M | 73.87M | 82.03M | 82.39M | 34.68M |
| Current Liabilities | - | 18.27M | 26.78M | 26.00M | 42.62M | 43.04M | 37.80M | 25.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.22M | -13.63M | -15.45M | -21.43M | -21.76M | -22.66M | -44.81M |
| Investing Cash Flow | -577.00K | -640.00K | -369.00K | -540.00K | 14.21M | -474.00K | 78.56M |
| Financing Cash Flow | 7.98M | 51.21M | 6.71M | 8.54M | 9.84M | 17.09M | -10.64M |
| Capital Expenditure | -577.00K | -640.00K | -369.00K | -540.00K | -346.00K | -654.00K | -1.88M |
| Free Cash Flow | -7.80M | -14.27M | -15.81M | -21.97M | -22.11M | -23.31M | -46.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 46.1% | 48.2% | 40.1% | 48.8% | 44.7% | 46.4% | 53.7% |
| Operating Margin % | -19.6% | -31.9% | -48.6% | -147.5% | -123.4% | -212.3% | -218.9% |
| Net Margin % | -27.8% | -51.1% | -52.4% | -137.9% | -152.2% | -372.9% | 434.2% |
| ROE % | 21.7% | -104.8% | -183.7% | 653.6% | 97.6% | 116.6% | 192.9% |
| ROCE % | -31.7% | -24.3% | -55.9% | -134.2% | -7,807.2% | 1,841.2% | -72.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELUT
Elutia sets 5 p.m. ET webcast for Q2 results on Aug. 13 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNVHJGQUVhM1NqTTVDQ3dNWGhuZy13U08zZzU0blpzd1BuMGlFeG1KaUtsOHQxOFVxNWhmSVBNdGtjeWYzX0NEaHZIOVlzbDVTUEpSNDdRYWF0VmJPRW1DNlpMOVIySXQ1SnJUUk9CZUtOSVRfQXI4ZnAwMW41Rkdual9PbGo2M0pvYmNaVE…
Elutia, Inc. Revenue Breakdown – NASDAQ:ELUT - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5EWjVBQTJ4dm1pTWc3ck9yNXFoODhYNkZxMDJjcnhzaTZFWmc3Z014c3kyaEJUb05HTnlSeXJlVXFhck84T2t5RUVFVno0Zm9MNGV2UXhiVElwZW4yWkZnWHJVZk5vNW91QWpKVVB6eEJtcl9fcFVJ?oc=5" target="_blank">Elutia,…
Lake Street Reaffirms Their Buy Rating on Elutia (ELUT) - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWER0OWt2YXdmVllaMEdvNTZ6LUZNbEFycmFmN0t5NUtRUGNNVDZEMUFEOHhZX2VPRERlZjZCcFRkREN0QTVoZmNhS1RBNlhPNTVjYThURWkzQlpXQjB3aUM0OXJBMEVuQUFUX0FXajdNRTNIWDJiLVdVOGFHUGQxNjlELTdlcXZwaDRpS2…
Elutia Targets Breast Cancer Surgery Where Complications Reach 1 in 3 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTV9Jb0RqMXRSOFpGdG1HUjI2N2doT0hkZTdfSHhYY3JkRkpncFZzRmt3VFh3cmxSYTU0dUd6Q3RpdzdraE9QOXdfZC1wS0pXVVR5Nm5sa0JKdEJWVlgyUmQ4dVlFVXU1UFpKQ2pyWVk3SnhjSERFRHFJWThwNGVXaDRmeWpwRmdsT0tvdk…
ELUT|Elutia Inc|Price:0.854|Chg%:-0.003 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE4talAxcExwZUZxd2pFWXljTDhVdTZFckJDNlBfUVRhRnlNdE9HcnNNMUpxcWpWTUJrN1V3WHF2azRMU3FNb0swQThvZFdKU003b2V3RGowN3d3MWJIdmxydzJqZS00MFUxWGJyc0N3?oc=5" target="_blank">ELUT|Elutia Inc|Pri…
ELUT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9PYkxJRUlLMGZRVFlrdFlOZGVXNXZJeTVnTzN3NmxpS0o0U0xtRnlCNllFdkRDU3Q3amNzSGw0bGtxWWs4ZTZGX05JeURUb29IQ1l2SERKUTBEbmVDU3hTNkJRNWNyN1dSTGVPWF9ON1NiVGl6cGZ3cGpB?oc=5" target="_blank">ELU…
ELUT — Frequently Asked Questions
What is the current share price of ELUT?
As of 2026-08-05 17:25 PDT, ELUT trades at $0.87 on NASDAQ/NYSE. Its 52-week range is $0.50 to $2.40.
What is the P/E ratio of ELUT?
ELUT trades at a trailing price-to-earnings (P/E) ratio of 1.00.
Is ELUT a good stock to buy?
This page provides a data-driven analysis of ELUT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.